Chorea is a hallmark of Huntington disease (HD) along with cognitive decline and psychiatric impairment. It often develops early, gradually worsening and plateauing in late stages.1 Motor dysfunction, including chorea, decreases functional capacity, particularly in early HD.Chorea worsens weight loss5 and can compromise safety, including increasing fall risk. Treating chorea is an important part of HD management.
The pathophysiology and neurochemical bases of HD are complex and incompletely understood. Dopamine and glutamate transmission and interactions are affected, contributing to striatal and cortical vulnerability and to features such as chorea.8 Most agents investigated for HD chorea target these neurotransmitters and receptors. Neuroprotective trials often focus on agents that may prevent oxidative stress or glutamatergic changes related to excitotoxic stress.、
For this evidence-based guideline, we asked the following question: For adult patients with HD requiring symptomatic chorea therapy, what available pharmacologic agents effectively reduce chorea as measured by validated scales?
版权声明
本网站所有注明“来源：丁香园”的文字、图片和音视频资料，版权均属于丁香园所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：丁香园”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。同时转载内容不代表本站立场。
神经系统疾病相关文章
